Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 14c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.74 +0.20%
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Piper Sandler Reiterates Overweight Rating on Reddit (RDDT)
- SanDisk surges as Meta memo confirms multi-year flash storage deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
